Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.

Challenger Exploration Limited ( ($AU:CEL) ) has issued an announcement. Challenger Gold Limited announced that all resolutions proposed at its ...

The annual CEL & Associates Inc. Tenant Satisfaction Survey is scheduled to run for a 60-day period beginning on Monday, ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

Reports FY24 revenue $107.9M, consensus $121.7M. “2024 was a transformational year for Arcellx (ACLX) as our ASH data presentations for ...

Wheel World is also a significant step up from developer Messhof's previous pixel art side-scrolling fighting game series ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

VIENNA, Va., February 20, 2025--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial. VIENNA, Va., February 18, 2025--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows ...

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for ...

Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...